Cytek Biosciences, Inc. (CTKB) Misses Q1 EPS by 5c ; Offers Guidance

Cytek Biosciences, Inc. (NASDAQ: CTKB) reported Q1 EPS of ($0.15), $0.05 worse than the analyst estimate of ($0.10). Revenue for the quarter came in at $44.1 million versus the consensus estimate of $43.95 million.

GUIDANCE:

Cytek Biosciences, Inc. sees FY2026 revenue of $205-212 million, versus the consensus of $208.2 million.

For earnings history and earnings-related data on Cytek Biosciences, Inc. (CTKB) click here.

You May Also Be Interested In

• Trump on Iran: we're trying to work out a deal that's fair
• Tellus Power and Nayax partner on integrated EV charging platform
• Korn Ferry (KFY) Tops Q4 EPS by 2c, Beats on Revenue; Offers Q1 Guidance